Skip to main content
Clinical Trials/CTRI/2026/01/102172
CTRI/2026/01/102172Not yet recruitingNot Applicable

To evaluate and compare the in vivo safety and efficacy of two hair care formulations in terms of reduction in dandruff effect on healthy human subjects

Glenmark Pharmaceuticals Ltd.1 site in 1 country72 target enrollmentStarted: February 7, 2026

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
72
Locations
1

Study Overview

Brief Summary

OBJECTIVE :The objective of this study will be to evaluate & compare the in-vivo safety and efficacy of two hair care formulations in terms of reduction in dandruff effect on healthy human subjects The evaluation will be performed using:Subject’s Self Evaluation, Dermatological Evaluation: Cosmetic Acceptability, Dermatological Evaluation: Efficacy, Corneometry, Photographs of scalp build-up by Dino-lite

POPULATION :72 (36 Males and 36 Females) subjectswill be selected for the study.The subjects selected for this study are healthy males & females, aged between 18 and 35 years old having moderate to severe dandruff (at least shoulder length hair for Females)

STUDY DURATION : 70 days including the 14 days conditioning period, 28 days application period and 28 days Reoccurrence period.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 35.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Indian Asian male & females subjects.
  • Healthy subjects.
  • Skin is healthy on the studied anatomic unit 4)Having moderate to severe dandruff.

Exclusion Criteria

  • For Females: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2)Having refused to give his/her assent by not signing the consent form 3)Taking part in another study liable to interfere with this study 4)Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 5)Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 6)Having a progressive asthma (either under treatment or last fit in the last 2 years) 7)Being epileptic 8)Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 9)Having cutaneous hypersensitivity 10)Following a chronic or intermittent medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, anti-coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 11)Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months 12)Having changed his/ her cosmetic habits except those required by the protocol in the 14 days preceding the start of the study on the studied anatomic unit 13)Having applied a hair care product on studied area the first day of the study (hair should be washed with the provided neutral shampoo two days prior to the day of visit.) 14)Having applied a hair care product on study visits (hair should be washed with the provided test product two days prior to the day of study visits.).

Investigators

Sponsor
Glenmark Pharmaceuticals Ltd.
Sponsor Class
Pharmaceutical industry-Global
Responsible Party
Principal Investigator
Principal Investigator

Dr Niharika Salian

MASCOT-SPINCONTROL India Pvt. Ltd.

Study Sites (1)

Loading locations...

Similar Trials